Over the last decade, significant innovation has taken place with regards to our mechanistic understanding of immunization to alloantigens on transfused red blood cells (RBCs). Mechanistic innovation has been driven largely by advanced animal modeling that has led to follow up human studies. Conversely, innovative human studies have also led to new questions that have resulted in advances in animal models. In this bidirectional use of animal and human studies, substantial progress has been made in both mechanistic understanding, human epidemiology, and the generation of potential therapeutic interventions. Moreover, the combination of animal and human studies have allowed a careful determination of what basic findings do, or do not, translate into human biology – providing a careful strategic metric for relevant and translatable scientific inquiry. This session serves to inform the audience of recent advances and also communicate the current existing landscape of tools and systems available for ongoing discovery.
Define critical mechanistic components of the humoral immune response to transfused red blood cells.
Incorporate recent advances in our understanding of alloimmunization into their conceptualization of the clinical problem as well as potential prevention and/or mitigation strategies.
Explain the level of our current understanding and the state of the art tools available for ongoing investigation.